PMAs BASED ON "LEAST BURDENSOME" STUDIES MUST BE JUSTIFIED BY SPONSORS IN PRE-SUBMISSION MEETINGS, FDA's BURLINGTON SAYS; PROVISION TAKES EFFECT FEB. 20
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application sponsors must prove in pre-submission meetings with FDA why less burdensome trials are an acceptable alternative to "the highest quality scientific approach," FDA Center for Devices and Radiological Health Director Bruce Burlington said at a Dec. 3 videoconference sponsored by the Food & Drug Law Institute. Burlington's comment came during a discussion of the FDA Modernization Act's provision on pre-submission meetings.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.